Fig. 3

OS in patients with LM depending on EGFR status. a EGFR wild-type NSCLC patients who received standard first-line chemotherapy presented a clear benefit in terms of OS when liver was not involved (n = 96) compared to those patients with LM (n = 45). b No differences were observed in EGFR mutated population receiving first line TKI in terms of OS when comparing patients with no LM (n = 13) with patients with liver involvement (n = 4).